Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails AnalysiPosted by saikrishna on May 29th, 2018 Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Amyotrophic Lateral Sclerosis Pipeline Drugs AssessmentOverview: Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron system, enables destroy nerve cells and causes disability. Amyotrophic lateral sclerosis is known as Lou Gehring’s disease. Amyotrophic lateral sclerosis often begins with muscle twitching and weakness in a limb, or slurred speech. Afterwards, may affects the control of the muscles involved in movement, speaking, eating and breathing. There is no cure for the disease and eventually disease is fatal. The disease is inherited in 5% to 10% of cases and rest is unknown etiology. Researchers are studying several possible causes including gene mutation, chemical imbalance, and protein mishandling and disorganized immune response.Amyotrophic lateral sclerosis is difficult to diagnose, because it mimics various neurological disease symptoms. Generally ALS diagnosed using electromyogram, nerve conduction study, MRI, spinal tap and muscle biopsy. Blood and urine test are performed to sort out the other possible signs and symptoms. Two FDA approved drugs are available in the market, namely Riluzole and endaravone. Various therapies are available to reduce the symptoms of the disease. A sample of this report is available upon request @ Segmentation: The pipeline drugs are segmented based on route of administration, trial phase,and company By route of administration, amyotrophic lateral sclerosis pipeline drugs are segmented into
By trial phase, amyotrophic lateral sclerosis pipeline drugs are segmented into
By company, amyotrophic lateral sclerosis pipeline drugs are segmented into
Like it? Share it! More by this author |